Form 4: Trevi Therapeutics Executive Thomas Sciascia Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, reports the exercise of stock options and subsequent sale of shares on March 25, 2025.

Summary

  • On March 25, 2025, Thomas Sciascia, the Chief Scientific Officer of Trevi Therapeutics, exercised stock options to acquire 2,631 shares of common stock at a price of $1.43 per share.
  • Simultaneously, Sciascia sold 2,631 shares of common stock at a price of $6.6 per share.
  • Following these transactions, Sciascia directly owns 221,373 shares of Trevi Therapeutics common stock.
  • The exercised stock options were granted on May 15, 2015, and vested over a period from May 15, 2016, to May 15, 2019.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by an executive, and doesn't inherently indicate positive or negative sentiment. The exercise and sale could be for various personal financial reasons.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Key Dates

DateDescription
May 15, 2015Date stock options were granted.
May 15, 201625% of the shares underlying the option vested.
May 15, 2019Remaining 75% of the shares vested in equal monthly installments.
March 25, 2025Date of stock option exercise and sale of shares.
March 26, 2025Date of signature on the Form 4 filing.

Keywords

Trevi Therapeutics, TRVI, Sciascia, Stock Options, Form 4, Executive Compensation, Insider Trading, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.